Related Experiment Video
Updated: Aug 23, 2025
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Theaflavin-3,3'-Digallate Plays a ROS-Mediated Dual Role in Ferroptosis and Apoptosis via the MAPK Pathway in Human
Tao He1,2,3,4, Xiaohong Lin5, Chaohua Yang1,2,3
1Chongqing Medical University, Chongqing 400016, China.
Abstract:
Globally, osteosarcoma (OS) is the most prevalent form of primary bone cancer in children and adolescents. Traditional neoadjuvant chemotherapy regimens have reached a bottleneck; thus, OS survivors have unsatisfactory outcomes. Theaflavin-3,3'-digallate (TF3) exhibits potent anticancer properties against many human cancers. Nevertheless, the biological effects and the underlying molecular mechanism of TF3 in human OS remain unclear. The objective of this study was to investigate the effects of TF3 on human OS cell lines and mouse xenograft models. The results showed that TF3 reduced cell viability, suppressed cell proliferation, and caused G0/G1 cell cycle arrest in both MG63 and HOS cell lines in a concentration-dependent manner. TF3 also altered the homeostatic mechanisms for iron storage in the examined cell lines, resulting in an excess of labile iron. Unsurprisingly, TF3 caused oxidative stress through reduced glutathione (GSH) exhaustion, reactive oxygen species (ROS) accumulation, and the Fenton reaction, which triggered ferroptosis and apoptosis in the cells. TF3 also induced MAPK signalling pathways, including the ERK, JNK, and p38 MAPK pathways. Furthermore, oxidative stress was shown to be the primary reason for TF3-induced proliferation inhibition, programmed cell death, and MAPK pathway activation in vitro. Moreover, TF3 exhibited markedly strong antitumour efficacy in vivo in mouse models. In summary, this study demonstrates that TF3 concomitantly plays dual roles in apoptotic and ferroptotic cell death by triggering the ROS and MAPK signalling pathways in both in vitro and in vivo models.
Insights
Theaflavin-3,3-digallate (TF3) shows promise against osteosarcoma by inducing cell death and halting proliferation. This compound triggers oxidative stress and activates key signaling pathways, offering a potential new avenue for treating this bone cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma (OS) is a primary bone cancer affecting children and adolescents, with limited treatment options and poor outcomes.
- Traditional chemotherapy for OS has plateaued, necessitating novel therapeutic strategies.
- Theaflavin-3,3'-digallate (TF3), a compound with known anticancer properties, has not been fully investigated in the context of human OS.
Purpose of the Study:
- To investigate the anti-cancer effects of TF3 on human osteosarcoma cell lines.
- To elucidate the molecular mechanisms underlying TF3's action in osteosarcoma.
- To evaluate TF3's efficacy in a mouse xenograft model of osteosarcoma.
Main Methods:
- TF3 treatment of human OS cell lines (MG63 and HOS) and mouse xenograft models.
- Assessment of cell viability, proliferation, and cell cycle progression.
- Analysis of iron homeostasis, oxidative stress markers (GSH, ROS), and cell death pathways (apoptosis, ferroptosis).
- Investigation of MAPK signaling pathway activation (ERK, JNK, p38).
Main Results:
- TF3 reduced OS cell viability and proliferation, inducing G0/G1 cell cycle arrest in a dose-dependent manner.
- TF3 disrupted iron homeostasis, leading to iron excess, oxidative stress (GSH depletion, ROS increase), and triggering both apoptosis and ferroptosis.
- TF3 activated MAPK signaling pathways (ERK, JNK, p38), with oxidative stress identified as the primary driver of these effects and anti-tumor activity.
- Significant tumor growth inhibition was observed with TF3 treatment in vivo.
Conclusions:
- TF3 demonstrates potent anti-osteosarcoma activity both in vitro and in vivo.
- TF3 induces programmed cell death through a combination of apoptosis and ferroptosis, driven by oxidative stress.
- TF3's mechanism involves the modulation of iron metabolism and activation of MAPK signaling pathways, presenting a dual-action therapeutic potential.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023